Reply to: Comment: Detection of Vaccine Adverse Events Before Package Insert Revisions Using a Japanese Spontaneous Reporting System

被引：0

作者：

Suzuki, Shimon ^{[1
]}

Imai, Shungo ^{[1
,3
]}

Mitsuboshi, Satoru ^{[1
,2
]}

Kizaki, Hayato ^{[1
]}

Hashiguchi, Masayuki ^{[1
]}

Hori, Satoko ^{[1
]}

机构：

[1] Keio Univ, Fac Pharm, Div Drug Informat, Tokyo, Japan

[2] Kaetsu Hosp, Dept Pharm, Niigata, Japan

[3] Keio Univ, Fac Pharm, Div Drug Informat, 1-5-30 Shibakoen,Minato Ku, Tokyo 1058512, Japan

来源：

JOURNAL OF CLINICAL PHARMACOLOGY | 2023年 / 63卷 / 10期

关键词：

D O I：

10.1002/jcph.2323

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：1171 / 1171

页数：1

共 50 条

[41] Comparison of signal detection of tumour necrosis factor-α inhibitors using the Korea Adverse Events Reporting System Database, 2005-2016
Ha, Dongmun
Lee, Seung Eun
Song, Inmyung
Lim, Sung Jun
Shin, Ju-Young
CLINICAL RHEUMATOLOGY, 2020, 39 (02) : 347 - 355
[42] A retrospective analysis of adverse drug events leading to hospitalization or prolonged hospitalization in Saudi Arabia using the Saudi food and drug authority (SFDA) spontaneous reporting system
AlQadheeb, Eman Khalid
Alblowi, Fotoun
Alolayet, Rayan Ibrahim
Al-Sadaawi, Asma
Alharbi, Muhanad
AlShahrani, Mobarak
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 459 - 459
[43] Empirical Bayesian Data Mining as an FDA Tool for Prospective Early Detection of Novel Safety Signals in the Vaccine Adverse Events Reporting System (VAERS): A Case Study of Febrile Seizures after an Influenza Virus Vaccine
Menschik, David
Martin, David
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2011, 20 : S241 - S241
[44] Comment on: Frequency and Associated Costs of Anaphylaxis- and Hypersensitivity-Related Adverse Events for Intravenous Iron Products in the USA: An Analysis Using the US Food and Drug Administration Adverse Event Reporting System
Michael Auerbach
Drug Safety, 2021, 44 : 609 - 610
[45] Comment on: Frequency and Associated Costs of Anaphylaxis- and Hypersensitivity-Related Adverse Events for Intravenous Iron Products in the USA: An Analysis Using the US Food and Drug Administration Adverse Event Reporting System
Auerbach, Michael
DRUG SAFETY, 2021, 44 (05) : 609 - 610
[46] Authors' Reply to Noguchi's comment on: "Drug-Drug Interaction of the Sodium Glucose Co-transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data"
Gamble, John-Michael
Alkabbani, Wajd
DRUG SAFETY, 2022, 45 (07) : 813 - 814
[47] Preliminary Analysis of Association Between COVID-19 Vaccination and Sudden Hearing Loss Using US Centers for Disease Control and Prevention Vaccine Adverse Events Reporting System Data
Formeister, Eric J.
Chien, Wade
Agrawal, Yuri
Carey, John P.
Stewart, C. Matthew
Sun, Daniel Q.
JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2021, 147 (07) : 672 - 674
[48] Comparison of signal detection between statin and statin/ezetimibe fixed-dose combination using the Korea Adverse Events Reporting System Database, 2005-2016
Ha, Dongmun
Lee, Yeon-Ju
Chun, Yoonsoo
Shin, Ju-Young
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2019, 57 (10) : 489 - 499
[49] Authors’ Reply to Noguchi’s comment on: “Drug-Drug Interaction of the Sodium Glucose Co-transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data.”
John-Michael Gamble
Wajd Alkabbani
Drug Safety, 2022, 45 : 813 - 814
[50] Comparison of thrombotic adverse events in patients treated with factor VIII products and emicizumab using the 2018-2022 US Food and Drug Administration Adverse Event Reporting System data: comment from Berkowitz et al.
Berkowitz, Callie
Wilson, Samuel
Key, Nigel S.
Ellsworth, Patrick
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2024, 22 (09) : 2674 - 2675

← 1 2 3 4 5 →